Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.
When prostacyclin (5 ng kg-1 min-1) was given during dialysis it enhanced the biological activity of heparin and prevented the activation and consumption of platelets. No adverse effects were observed. The reduction in heparin requirements produced by prostacyclin should make dialysis, safer, particularly for patients at risk of bleeding, while preserving the biocompatibility of the dialysis circuit. It remains to be established whether prevention of platelet activation will confer long-term benefit by inhibiting the prothrombotic state induced by haemodialysis, thereby reducing the risk of atherosclerosis in uraemic patients.
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011453:Prostaglandins / Q000494:pharmacology*; D006435:Renal Dialysis; D013918:Thrombin Time
D011453:Prostaglandins; D006493:Heparin; D011464:Epoprostenol